The PROGRESS IV clinical trial will evaluate the safety and clinical effectiveness of autologous protein solution (APS), prepared from a small sample of a patient’s own blood with an investigational device called the nSTRIDE® APS Kit, on pain and function associated with knee osteoarthritis (OA).
Osteoarthritis, the most common type of arthritis, is a progressive disease of the joints.1, 4 Often referred to as “wear and tear” arthritis, OA occurs when the top layer of cartilage, the slippery tissue that covers the ends of bones in a joint and helps absorb the shock of movement, breaks down and wears away.4, 5 The bones under the cartilage then rub together, causing pain, swelling and loss of motion in that joint. Eventually, the joint may lose its normal shape and/or develop bone spurs around its edges.5